The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis

Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy with a variable clinical outcome. Biomarkers of CLL progression are required for optimising prognosis and therapy. The Inhibitor of Bruton’s tyrosine kinase—isoform α (IBTKα) gene encodes a substrate receptor of Cullin 3-depend...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cell Death Dis
Egile Nagusiak: Albano, Francesco, Chiurazzi, Federico, Mimmi, Selena, Vecchio, Eleonora, Pastore, Arianna, Cimmino, Clementina, Frieri, Camilla, Iaccino, Enrico, Pisano, Antonio, Golino, Gaetanina, Fiume, Giuseppe, Mallardo, Massimo, Scala, Giuseppe, Quinto, Ileana
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5849039/
https://ncbi.nlm.nih.gov/pubmed/29317636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0026-3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak